VRTXCongressional Stock Trades
Vertex Pharmaceuticals Inc
Pharmaceutical Preparations
Congressional stock trades in Vertex Pharmaceuticals Inc (VRTX) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.
Total Trades
10
Politicians Trading
4
Last Traded
Aug 26, 2026
Trading History
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| David TaylorR | Sep 2, 2025 | Aug 7, 2025 | Buy | $1,001 - $15,000 | +35.33% |
| Jefferson ShreveR | Apr 11, 2025 | Mar 13, 2025 | Buy | $15,001 - $50,000 | +1.08% |
| Jefferson ShreveR | Mar 9, 2025 | Feb 24, 2025 | Buy | $15,001 - $50,000 | +5.54% |
Price History
About Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.